TearCare MGX™ System With and Without Warming Hold
← catalyst calendarSponsored by Sight Sciences, Inc. (industry) · SGHT — their whole pipeline →.
Phase
Not applicable
Status
Completed
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
21actual
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-03-17 | actual | When the study began enrolling |
| Primary completion | 2026-05-19 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-05-19 | actual | The whole study's end, after follow-up |
| First posted | 2026-01-26 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-05 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Meibomian Gland Dysfunction (Disorder)
Intervention
- Device: localized heat therapy
Primary outcome
what the primary-completion date above is the date OFMean difference between eyes in Meibomian Gland Secretion Score (MGSS)
measured MGSS used to calculate the difference in MGSS between eyes is obtained post-treatment at the procedure visit (Day 0).
Permalink · SGHT's whole pipeline · Catalyst calendar · Every registered study · What changed